Published in Strahlenther Onkol on April 26, 2011
Radiotherapy in marginal zone lymphoma. Radiat Oncol (2013) 0.77
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 8.53
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst (2009) 3.83
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol (1999) 2.36
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs (2003) 2.30
Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 1.59
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol (2008) 1.56
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol (2000) 1.28
Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol (1996) 1.26
Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol (2002) 1.01
Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol (2008) 0.97
The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol (2010) 0.93
Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration (2007) 0.90
Second malignancies in high‑dose areas of previous tumor radiotherapy. Strahlenther Onkol (2010) 0.90
Low-grade non-hodgkin lymphomas. Semin Radiat Oncol (2007) 0.87
Reproducibility of patient positioning for fractionated extracranial stereotactic radiotherapy using a double-vacuum technique. Strahlenther Onkol (2004) 0.86
Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res (2000) 0.85
Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res (2006) 0.85
Nodal follicular lymphoma: the role of radiotherapy for stages I and II. Strahlenther Onkol (2010) 0.84
Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy. Strahlenther Onkol (2009) 0.83
Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma. Strahlenther Onkol (2003) 0.81
[Follicle centre lymphoma: treatment results for stage I and II]. Strahlenther Onkol (2003) 0.79
Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol (2001) 0.77
Stage I-II low grade non-Hodgkin's lymphoma: prognostic factors and treatment results. Strahlenther Onkol (1992) 0.76
Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients. Strahlenther Onkol (2010) 0.75
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer (2009) 1.99
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol (2008) 1.91
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica (2006) 1.66
Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med (2009) 1.64
Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys (2003) 1.57
Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol (2003) 1.52
Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol (2003) 1.51
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst (2014) 1.46
Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol (2005) 1.43
Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma (2006) 1.41
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood (2009) 1.37
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology (2003) 1.30
Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol (2002) 1.27
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging (2015) 1.18
Inferential reasoning by exclusion in pigeons, dogs, and humans. Anim Cogn (2008) 1.15
Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respir Res (2007) 1.14
Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer (2002) 1.13
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol (2011) 1.09
Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol (2004) 1.08
The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer (2008) 1.08
Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics (2008) 1.03
Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol (2008) 1.03
Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer (2002) 1.01
Providing psychosocial support for breast cancer patients based on screening for distress within a consultation-liaison service. Psychooncology (2004) 0.99
Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother Oncol (2010) 0.99
Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (2005) 0.99
Epidemiological aspects of hadron therapy: a prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO). Radiother Oncol (2004) 0.98
Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys (2008) 0.98
Alternative splicing of vasohibin-1 generates an inhibitor of endothelial cell proliferation, migration, and capillary tube formation. Arterioscler Thromb Vasc Biol (2008) 0.98
Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson (2002) 0.98
Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol (2008) 0.97
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. PLoS One (2013) 0.97
Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med (2004) 0.97
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol (2005) 0.97
Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer (2009) 0.95
Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: sequence implementation and data analysis. J Magn Reson Imaging (2007) 0.94
Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry. BMC Res Notes (2008) 0.94
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol (2012) 0.93
Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer. Ann Surg Oncol (2012) 0.92
Disseminated infection with Prototheca zopfii after unrelated stem cell transplantation for leukemia. J Clin Microbiol (2004) 0.92
Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Dis Markers (2008) 0.92
Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation (2003) 0.92
CD34+/CD133- circulating endothelial precursor cells (CEP): characterization, senescence and in vivo application. Exp Gerontol (2006) 0.92
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys (2005) 0.91
Visual categorization of natural stimuli by domestic dogs. Anim Cogn (2007) 0.91
MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res (2007) 0.90
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer (2014) 0.89
Breaking the rules? X-ray examination of hematopoietic stem cell grafts at international airports. Blood (2002) 0.88
Intraoperative radiotherapy of soft tissue sarcoma of the extremity. Strahlenther Onkol (2004) 0.88
Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI). Magn Reson Imaging (2003) 0.87
Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol (2013) 0.86
Diagnostic and therapeutic challenges of a large pleural inflammatory myofibroblastic tumor. Case Rep Pulmonol (2012) 0.86
Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol (2011) 0.86
Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation. Hum Pathol (2002) 0.86
Natural killer cell functions mediated by the neuropeptide substance P. Regul Pept (2003) 0.86
Reproducibility of patient positioning for fractionated extracranial stereotactic radiotherapy using a double-vacuum technique. Strahlenther Onkol (2004) 0.86
Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res (2006) 0.85
"Idiopathic Bence-Jones proteinuria": a new characterization of an old entity. Ann Hematol (2013) 0.84
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines. Mol Cancer Ther (2007) 0.84
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther (2009) 0.84
Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer (2005) 0.83
Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica (2013) 0.83
Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clin Appl (2008) 0.82
Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother (2005) 0.82
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood (2006) 0.82
Compensating for tumor motion by a 6-degree-of-freedom treatment couch: is patient tolerance an issue? Int J Radiat Oncol Biol Phys (2009) 0.82
Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report. Strahlenther Onkol (2003) 0.81
Molecular therapies for malignant glioma. Wien Med Wochenschr (2006) 0.81
New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. Oncology (2014) 0.81
Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol (2009) 0.81
Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Thromb Haemost (2010) 0.80
3-D-conformal radiation therapy for pediatric giant cell tumors of the skull base. Strahlenther Onkol (2002) 0.80
In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. J Hematother Stem Cell Res (2002) 0.80
Photons or protons: precision radiotherapy of lung cancer. Strahlenther Onkol (2007) 0.80
Profilin 1: do we have a novel proteome-found biomarker predicting response to anticancer therapy? Proteomics (2013) 0.80
Postoperative morbidity following chemoradiation for locally advanced low rectal cancer. J Gastrointest Surg (2008) 0.80
Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood (2005) 0.80
Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol Cancer Ther (2004) 0.79
Hodgkin lymphoma in Tyrol-a population-based study. Ann Hematol (2008) 0.79
Polyarteritis nodosa complicating multiple myeloma - a case report and review of the literature. Clin Neuropathol (2014) 0.79